Lisata announces publication of case report on patient treated with LSTA1

Lisata Therapeutics announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination with the standard-of-care therapy in Oncology & Cancer Case Reports Journal on December 30, 2023. The case report, entitled “LSTA1 Potentiates Complete Response in Metastatic Gastroesophageal Adenocarcinoma,” details a patient with metastatic gastroesophageal adenocarcinoma who achieved a complete response when given LSTA1, Lisata’s lead investigational product, in combination with standard of care FOLFIRINOX + pembrolizumab. The subject initially underwent months of SoC treatments and achieved a partial response. Upon subsequent addition of LSTA1 to such SoC therapeutic regimen, the subject achieved a complete response, confirmed both radiographically and surgically. Kristen Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata said, “Despite advances using immunotherapy and chemotherapy as SoC for metastatic disease and the modest survival improvement therein, the long-term prognosis for patients with metastatic gastroesophageal adenocarcinoma cancer remains poor. As detailed in the case report, LSTA1, together with the SoC therapy, demonstrated tumor targeting and penetration-enhancing capability in this patient. As this result implies, LSTA1, when administered in addition to SoC, is expected to improve outcomes for patients with a range of advanced solid tumors.”